Updates

Alliance Pharma - Acquires new products

September 2012

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Alliance Pharma, which is building by acquisition a portfolio of generic drugs, has just announced the purchase of three anti malarial brands, Paldurine, Savarine and Avloclor, which are sold mainly in the UK and France. Alliance is paying an initial £4.2m for these products, which are expected to contribute £1.1m to operating profit before finance costs. The deal is being funded through existing cash balances of its £20m bank facility, taking total draw-down to £8.5m. This purchase is timely because Alliance earlier announced a disappointing pre-close trading update with turnover expected to decline 10% to £22m in H1. While the well flagged reduction in sales of Deltacortril was th ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Informa - Net debt falls again

ITE Group - 96% forecast revenues booked

Alliance Pharma (July 2013)

Alliance Pharma (June 2012)

Alliance Pharma (November 2011)

Alliance Pharma - Cambridge Labs nehind its growth (June 2011)

Alliance Pharma (October 2010)

Alliance Pharma (August 2010)

Alliance Pharma - Trading ahead of expectations (July 2010)

Alliance Pharma - Gain reaches 75% in five months (May 2010)

Alliance Pharma - Substantial eps enhancing acquisition (March 2010)

Alliance Pharma - Beats expectations again (February 2010)

Alliance Pharma - Branded pharmaceuticals firm going great guns but cheap on PE of 6.7 (December 2009)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X